According to the NCT01295827 study, pembrolizumab monotherapy demonstrated durable antitumor activity and high five-year OS rates, particularly in patients with a PD-L1 tumor proportion score of 50% or greater, showing a five-year OS rate exceeding 25% [224]. This evidence concerns the gene CD274 and neoplasm.